Cargando…
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
Classical Hodgkin lymphoma is considered a highly curable disease; however, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. Current clinical parameters do not allow accurate risk stratification, and personalized therapies are lacking. In fact, Hodgkin...
Autores principales: | Derenzini, Enrico, Younes, Anas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129642/ https://www.ncbi.nlm.nih.gov/pubmed/21542892 http://dx.doi.org/10.1186/gm240 |
Ejemplares similares
-
Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018) -
Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018) -
The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022) -
Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018) -
Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)